Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus sakei KCTC 10755BP
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical, Intranasal
01
Overview
Lactobacillus sakei KCTC 10755BP (also known as L. sakei proBio65) is a specific probiotic strain of lactic acid bacteria originally isolated from the traditional Korean fermented vegetable, kimchi. It is being developed and marketed by Probionic Corporation. Clinical studies have investigated its therapeutic potential for atopic eczema–dermatitis syndrome (AEDS) and chronic rhinosinusitis. For atopic dermatitis, oral supplementation has been shown to significantly improve disease severity (as measured by SCORAD scores) in children compared to placebo. It is also formulated as a topical emollient to improve skin barrier function. The proposed mechanisms of action are multifactorial, including the inhibition of *Staphylococcus aureus* growth, modulation of the immune system by reducing levels of IgE and interleukin-4, and decreasing serum levels of inflammatory chemokines CCL17 and CCL27, which are correlated with AEDS severity. It is being investigated and marketed in both live (probiotic) and heat-killed (paraprobiotic/postbiotic) forms.
- Brand names
- LactopyCubiomeBoyan-ILanto Sinus Probiotic Powder
- Other names
- Lactobacillus sakei proBio65L. sakei proBio65Latilactobacillus sakei proBio65
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on Lactobacillus sakei KCTC 10755BP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus sakei KCTC 10755BP.